If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially as antibiotic resistance grows. While it’s currently approved for females ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

Advertisement Advertisement Called Blujepa, the drug works differently than existing antibiotics. It targets two enzymes that E. coli uses to make more copies of itself when it generates and snips off ...

The approval of the new drug is based on positive results from the Phase III EAGLE-2 and EAGLE-3 trials.

GSK’s oral antibiotic Blujepa (gepotidacin) has been approved by the US Food and Drug Administration (FDA) to treat uncomplicated urinary tract infections (uUTIs). The drug, which is the first in a ...

A UTI is considered uncomplicated if it occurs ... According to the drugmaker, Blujepa works through a novel mechanism, inhibiting bacterial DNA replication. A U.S. commercial launch is planned ...